1.51
1.31%
-0.02
After Hours:
1.49
-0.02
-1.32%
Corvus Pharmaceuticals Inc stock is currently priced at $1.51, with a 24-hour trading volume of 90,571.
It has seen a -1.31% decreased in the last 24 hours and a -15.64% declined in the past month.
The chart indicates a potential bullish trend, as the stock is below the $1.51 pivot point. If it approaches the $1.45 support level, significant changes may occur.
Previous Close:
$1.53
Open:
$1.6
24h Volume:
90,571
Market Cap:
$74.05M
Revenue:
-
Net Income/Loss:
$-27.03M
P/E Ratio:
-1.7976
EPS:
-0.84
Net Cash Flow:
$-23.97M
1W Performance:
+11.03%
1M Performance:
-15.64%
6M Performance:
+27.97%
1Y Performance:
+51.00%
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Name
Corvus Pharmaceuticals Inc
Sector
Industry
Phone
650 900 4520
Address
863 Mitten Road, Suite 102, Burlingame, CA
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-18-23 | Initiated | Oppenheimer | Outperform |
Dec-01-21 | Resumed | Jefferies | Buy |
May-27-21 | Initiated | Cantor Fitzgerald | Overweight |
Feb-10-21 | Downgrade | Mizuho | Buy → Neutral |
Sep-12-19 | Initiated | Mizuho | Buy |
May-29-19 | Initiated | ROTH Capital | Buy |
Aug-24-17 | Upgrade | Credit Suisse | Underperform → Neutral |
May-01-17 | Downgrade | Credit Suisse | Neutral → Underperform |
Apr-18-16 | Initiated | Credit Suisse | Outperform |
Apr-18-16 | Initiated | Guggenheim | Buy |
View All
Corvus Pharmaceuticals Inc Stock (CRVS) Latest News
Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks
Zacks Investment Research
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
GlobeNewswire Inc.
Down -18.35% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround
Zacks Investment Research
Corvus (CRVS) Upgraded to Buy: What Does It Mean for the Stock?
Zacks Investment Research
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire Inc.
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024
GlobeNewswire Inc.
Corvus Pharmaceuticals Inc Stock (CRVS) Financials Data
Corvus Pharmaceuticals Inc (CRVS) Net Income 2024
CRVS net income (TTM) was -$27.03 million for the quarter ending December 31, 2023, a +34.57% increase year-over-year.
Corvus Pharmaceuticals Inc (CRVS) Cash Flow 2024
CRVS recorded a free cash flow (TTM) of -$23.97 million for the quarter ending December 31, 2023, a +12.18% increase year-over-year.
Corvus Pharmaceuticals Inc (CRVS) Earnings per Share 2024
CRVS earnings per share (TTM) was -$0.56 for the quarter ending December 31, 2023, a +37.08% growth year-over-year.
About Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
Cap:
|
Volume (24h):